About Third Pole
Third Pole Therapeutics focuses on developing solutions for cardiopulmonary diseases, primarily through medical devices and pharmaceuticals. Their main product is a portable inhaled nitric oxide device that enhances blood flow and oxygen delivery for patients with heart and lung conditions. Additionally, they have created eNOfit, a wearable platform for continuous nitric oxide delivery, which helps manage chronic conditions effectively. Unlike competitors, Third Pole emphasizes collaboration with top partners in the medical field to broaden their market presence and improve patient outcomes. Their goal is to provide advanced treatment options while adhering to high quality and compliance standards.
Waltham, MassachusettsHeadquarters
2014Year Founded
$93.1MTotal Funding
DEBTCompany Stage
Biotechnology, HealthcareIndustries
11-50Employees
Risks
Potential competition from similar nitric oxide delivery systems could impact market share.
Delays in FDA approval for eNOcare™ could hinder market entry and revenue growth.
Reliance on strategic partnerships poses risks if partnerships do not materialize as expected.
Differentiation
Third Pole offers a tankless inhaled nitric oxide device, unlike traditional tank-gas systems.
Their eNOfit platform is the first wearable drug-making platform for nitric oxide delivery.
Third Pole's products target cardiopulmonary diseases, a niche with limited advanced solutions.
Upsides
Third Pole received a $32M investment to accelerate its tankless iNO platform development.
The FDA's Breakthrough Devices Program could expedite Third Pole's product approvals.
Growing demand for portable medical devices boosts Third Pole's market expansion potential.
Funding
Total raised$93.13 M
Latest valuation$160.00 M
StageDEBT
DEBT
3/31/2024$5
LATE VC
3/31/2023$5
$160.00 MEARLY VC
11/30/2015$14
$69.00 M